Home About Clinicians Patients Investors Careers Media Contact Clinicians > About SIR-Spheres microspheres > Follow Up Response after treatment with SIR-Spheres® Y-90 resin microspheres may be evaluated by CT, MRI, PET and/or changes in tumour markers. Anatomical criteria (Response Evaluation Criteria In Solid Tumours - RECIST) can be misleading and may lead to an underestimation of the pathological tumour response, especially if determined early (<3 months). Imaging evaluation that incorporated necrosis indicators reported that response to treatment can become apparent earlier (one month).1 1. Keppke et al. Am J Roentgenol 2007; 188: 768-775. DOORwaY-90 Study International Recommendations FLEXdose Delivery Programme About SIRT About SIR-Spheres microspheres Mode of Action How are SIR-Spheres microspheres administered Patient Selection Potential adverse events Radiation Safety Aspects Follow Up Peri-Procedural Medications - mCRC Clinical Studies + HCC Clinical Studies + Ongoing Clinical Studies Customer Support and Training Programs Events Frequently Asked Questions Who we are Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. What are SIR-Spheres® Y-90 resin microspheres? SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. To view the Technical Bulletin regarding our indication, click here. Contact or follow us Contact Us SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Terms of Use | Privacy Information 892-EUA-1117 This content is intended for healthcare professionals only By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage. Yes Go to Homepage SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Click here to view our Technical Bulletin. Ok